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Abstract
Background Up to 50% of people with amyotrophic lateral sclerosis (ALS) experience cognitive dysfunction, whilst depres-
sion and anxiety are reported in up to 44% and 33%, respectively. These symptoms impact on quality of life, and are associated 
with a poorer prognosis. Historically, outcomes in clinical trials have focused on the effect of candidate drugs on physical 
functioning.
Methods We reviewed the past 25 years of clinical trials of investigative medicinal products in people with ALS, since the 
licensing of riluzole, and extracted data on frequency and type of assessment for neuropsychiatric symptoms and cogni-
tive impairment. Trial registry databases, including WHO International Trials Registry, European Clinical Trials Register, 
clinicaltrials.gov, and PubMed, were systematically searched for Phase II, III or IV trials registered, completed or published 
between 01/01/1994 and 31/10/2019. No language restrictions were applied. Outcome measures, exclusion criteria and 
assessment tool used were extracted.
Results 216 trials, investigating 26,326 people with ALS, were reviewed. 35% assessed neuropsychiatric symptoms, and 
22% assessed cognition, as Exclusion Criteria or Outcome Measures. 3% (n = 6) of trials assessed neuropsychiatric symp-
toms as a Secondary Outcome Measure, and 4% (n = 8) assessed cognition as Outcome Measures; only one trial included 
assessments for both cognition and neuropsychiatric symptoms as Outcome Measures. Three ALS-specific assessments 
were used in six trials.
Conclusions Trials for people with ALS have neglected the importance of neuropsychiatric symptoms and cognitive impair-
ment. Evaluation of these extra-motor features is essential to understanding the impact of candidate drugs on all symptoms 
of ALS.
PROPSERO registration CRD42020175612.
Keywords Amyotrophic lateral sclerosis · Motor neuron disease · Neuropsychiatric · Cognition · Clinical trials
Introduction
Amyotrophic lateral sclerosis (ALS) has been traditionally 
characterised as a disease of the motor system [1]; how-
ever, extra-motor symptoms, including neuropsychiatric 
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and cognitive symptoms, are now becoming more widely 
acknowledged as prevalent [2] and debilitating [3] features 
of this condition, and are predictive of disability [4].
Findings from a recent population-based study in Scot-
land reported a prevalence of neuropsychiatric disorders of 
19.7% in people with ALS, 70% of which were mood dis-
orders and 31.67% neurotic disorders (inclusive of anxiety, 
stress-related and somatoform disorders) [5].
The prevalence of these disorders in people with ALS is 
higher than that in the general population, 6.9% of whom 
meet thresholds for a depressive disorder and 14% an anxiety 
disorder [6, 7]. These differences remain when focusing on 
a group more representative of the general individual with 
ALS, the older adult population [8].
Cognitive impairment is an additional extra-motor feature 
of ALS that is highly prevalent, with some form of cognitive 
or behavioural symptoms experienced by 30–50% of people 
with ALS [9]. 15% of people with ALS meet diagnostic cri-
teria for frontotemporal dementia (FTD) [10, 11]. Cognitive 
impairment in people with ALS is characterised by executive 
dysfunction, impairments in language and social cognition 
[12–14], whilst apathy is the most pronounced behavioural 
change [15].
Individuals with chronic physical illness and comorbid 
depression or anxiety often experience a higher level of 
somatic symptom burden that can impair functioning [16]. 
Symptoms of depression, anxiety and apathy reduce quality 
of life (QoL) for people with ALS [17, 18]. Lower psycho-
logical well-being generally has been identified as predictive 
of disability and shorter survival in people with ALS [4]. 
Presence of concomitant neuropsychiatric conditions and 
cognitive impairment predicts greater carer distress [19–21].
Despite this, neuropsychiatric symptoms are often under-
recognised in clinical care. Assessments are often performed 
using tools which have not been adapted for people with 
physical disability or communication difficulties. Assess-
ments may also not be specifically addressing the cogni-
tive domains impaired in people with ALS, or providing 
disease-specific thresholds for impairment. Scores may be 
significantly impacted by the overlap of somatic features of 
neuropsychiatric conditions and those attributable to the pro-
gression of ALS. In a group that is predominantly affected 
by motor impairment, speech and respiratory difficulties, 
lengthy administration time can also reduce the suitability 
of an tool.
Assessment in clinical trials
The only globally licensed disease modifying therapy, 
riluzole [22], was introduced for use in people with ALS 
in the 1990s, following modest, but statistically signifi-
cant prolongation of survival by two to three months 
[23–25]. Edaravone (Radicava) and masitinib have both 
emerged as promising treatments following positive tri-
als in highly stratified cohorts [26], but neither have been 
licensed globally, owing to concerns around trial design 
and conduct. All of these current disease modifying thera-
pies are intended to target the motor symptoms of ALS. 
To this end, research is underway to improve our under-
standing of the molecular mechanisms underlying ALS. 
This may in turn reveal potential important therapeutic 
targets, including those that modulate cognition [27, 28]. 
Cognitive assessments have been included in some studies 
investigating the effects of rilzuole as a disease modify-
ing therapy in various other neurodegenerative conditions 
[29]. To our knowledge, the impact of riluzole on cogni-
tion in people with ALS has not been investigated in initial 
licensing trials.
There is an urgent need for more effective treatment 
options in ALS. Whilst survival and functioning remain 
the gold standard outcome measures used in clinical trials, 
incorporation of measures of neuropsychiatric and cognitive 
function enable more holistic assessment of the impact of 
drugs. Awareness of how a candidate drug may affect extra-
motor features is clinically revelant in disease management 
and quality of life.
Including individuals with neuropsychiatric and cognitive 
impairments, and using assessments to evaluate changes in 
these areas as outcome measures will enable the trial teams 
to evaluate the impact of the candidate drugs on people with 
extra-motor features of ALS.
Candidate drugs may have a selective effect on neuropsy-
chiatric or cognitive symptoms; therefore, measurement of 
these areas is pertinent to investigate the impact of an inves-
tigative medicinal product on both motor and extra-motor 
symptoms in ALS. The potential impact of candidate drugs 
is of therapeutic relevance, even if not the primary intended 
effect, considering the possible affect on quality of life and 
disease mangement of ALS.
Indeed, the 2019 revision of Airlie House consensus 
guidelines for design and implementation of ALS clinical 
trials [30] recommends that “Investigators may include 
assessments of cognitive or behavioral function as pri-
mary or secondary outcome measures”. Despite evolving 
guidance, and significant progess in establishing cognitive 
assessments within clinical care [31], we hypothesised that 
neuropsychiatric and cognitive symptoms have been under-
evaluated in clinical trials and that when assessed using 
standardised tools, these tools are not specifically designed 
for people with ALS, which may affect their suitability for 
use in this population.
We aimed to systematically review 25 years of clinical 
trials in ALS, since the licensing of riluzole, to identify if 
neuropsychiatric symptoms and cognitive impairment were 
evaluated. If they were evaluated, we assessed if this was as 
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an exclusion criteria or outcome measure and describe the 
tools used.
Methods
We completed a systematic, unbiased, search of trial reg-
istries including clinicaltrials.gov, World Health Organisa-
tion’s (WHO) International Clinical Trials Registry Platform 
(ICTRP), European Union Clinical Trials Register (Edu-
raCT) and PubMed on 18/11/2019 for Clinical Trials of an 
Investigational Medicinal Product (CTIMPs).
Using the search terms “amyotrophic lateral sclerosis” or 
“motor neuron* disease” we searched clinicaltrials.gov for 
interventional trials of investigative medicinal products. We 
searched European Union Clinical Trials Register (EduraCT) 
and WHO International Clinical Trials Registry Platform 
(ICTRP) for trials of “amyotrophic lateral sclerosis” with 
the filters “Phase II”, “Phase III” and “Phase IV” applied. 
Using the advanced search feature we filtered PubMed with 
[“amyotrophic lateral sclerosis”(MeSH Terms) OR “motor 
neuron* disease”(MeSH Terms)]. We then applied the ‘Clin-
ical Trial’ filter for Article Type, Human trials only and Pub-
lication Date within the criteria defined above.
Phase II, III or IV trials assessing potential disease modi-
fying therapies in subjects with amyotrophic lateral sclero-
sis that were registered, completed or published between 
01/01/1994 to 31/10/2019 were included. No language 
restrictions were applied. Extension trials, post-hoc analy-
sis papers and trials focused on symptom management were 
excluded.
Data extraction
The following details of selected trials were extracted: 
“Investigative Medicinal Product (IMP) Assessed”, “Num-
ber of Participants”, “Date of Commencement”, “Pri-
mary Outcome Measure(s)” and “Secondary Outcome 
Measure(s)”.
Assessment of neuropsychiatric conditions or cogni-
tive symptoms within each trial was categorised as fol-
lows: “Exclusion Criteria”, “Primary Outcome Measure”, 
“Secondary Outcome Measure”, “No Data Available for 
Trial” or “Not Assessed”. We also noted the assessment 
tool included, if documented, and a brief summary of the 
trial’s stipulations regarding neuropsychiatric conditions or 
cognitive symptoms. We also evaluated the use of Quality of 
Life measures within the trials. We investigated the number 
of clinical trials that recruited people with fronto-temporal 
dementia (FTD).
We documented the tools used and described the charac-
teristics of tools used to evaluate neuropsychiatric or cogni-
tive symptoms in trials identified in this systematic review. 
The areas assessed, features of administration and availabil-
ity of disease-specific scores were recorded.
Results
Overview
A total of 1,312 records were identified (see PRISMA dia-
gram in Fig. 1 for details). 296 duplicates were removed 
and a further 800 results were removed due to unsuitability 
(defined by inclusion criteria with full overview in Fig. 1); 
non-CTIMP and non-ALS subjects were the primary reasons 
for excluding search results. This resulted in 216 clinical tri-
als of investigative medicinal products. 216 trials, proposed 
to include a total of 26,326 participants with ALS, were 
included in the final review.
Only one trial, the Therapy in Amyotrophic Lateral Scle-
rosis (TAME) trial evaluating memantine (Barohn et al., cur-
rently recruiting, Trial ID: NCT02118727), assessed both 
neuropsychiatric symptoms and cognitive impairment as 
Secondary Outcome Measures. A full list of the 13 trials 
assessing neuropsychiatric symptoms and cognitive impair-
ment as primary or secondary outcome measures, the current 
status and results’ availability is shown in Table 1.
Four trials had results available. In the trial of memantine 
(NCT00353665) the use of Hamilton depression scale as a 
planned secondary outcome measure was noted in the trial 
record on clinicaltrials.gov; however, there was no discus-
sion of use or results of this outcome in the final report of 
the trial findings [32]. In a trial evaluating lithium carbon-
ate (EudraCT 2008–006,891-31), depression worsened and 
anxiety increased over time in participants, but there was no 
significant difference between study groups [33].
A trial of omigapil (NCT00072709) reported no change 
in neurocognitive evaluations, utilising the Addenbrooke’s 
Cognitive Examination (ACE) [34]. The triumeq trial 
(NCT02868580) assessed suicidal ideation as a secondary 
outcome measure using the Columbia Suicide Severity Rat-
ing Scale (C-SSRS). Only two participants (5% of total trial 
participants) reported suicidal ideation and this was deemed 
unrelated to triumeq [35].
Neuropsychiatric symptoms
35% (n = 76/216) of the total 216 trials included in this 
review assessed neuropsychiatric symptoms. Of these 76 
trials, 92% (n = 70/76) assessments were used as an Exclu-
sion Criteria, 3% (n = 2/76) as a Secondary Outcome Meas-
ure and 5% (n = 4/76) defined neuropsychiatric symptoms 
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as both a Secondary Outcome Measure and an Exclusion 
Criterion.
29% (n = 22/76) of the 76 trials that reported assess-
ing neuropsychiatric symptoms utilized investigator clini-
cal judgement, 32% (n = 24/76) clinical history or medical 
records and 11% (n = 8/76) specified a standardized assess-
ment tool.
Fig. 1  PRISMA Diagram for Record Selection. From Moher D, et al [71]. For more information, visit https ://www.prism a-state ment.org
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Cognitive impairment
21% (n = 46/216) of the 216 trials included assessed cogni-
tive functioning. Of these 46 trials assessing cognitive func-
tioning, 83% (n = 38/46) assessments were used as an Exclu-
sion Criteria, 4% (n = 2/46) as a Primary Outcome Measure 
and 13% (n = 6/46) as a Secondary Outcome Measure.
Of these 46 trials which reported assessing cognitive 
impairment and provided data on the method of assessment, 
23% (n = 11) utilized investigator clinical judgement, 9% 
(n = 4) clinical history or medical records and 26% (n = 12) 
specified a standardized assessment tool.
The Edinburgh Cognitive and Behavioural ALS Screen 
(ECAS) was the only assessment tool used as both a Primary 
and Secondary Outcome Measure to assess cognitive impair-
ment in people with ALS.
A comorbid diagnosis of dementia was an Exclusion 
Criteria in 32% (n = 69) of the 216 trials reviewed. Sub-
jects with dementia were explicitly referenced as able to 
participate in just 1% of trials (n = 3). 67% (n = 144) did not 
provide data on whether they accepted participants with a 
dementia diagnosis.
Quality of life measures were utilized as Primary and Sec-
ondary Outcome Measures in 1% (n = 3) and 27% (n = 59), 
respectively, of 216 trials reviewed. Table 2 summarises 
quality of life measures used and considers their content as 
some measures include limited assessments of mood and 
self-reported psychological health and functioning.
Characteristics of assessment tools identified
The only tool specifically designed and validated for neu-
ropsychiatric assessment in people with ALS, the ALS 
Depression Inventory (ADI-12) [36], was used in one trial. 
This tool is validated to screen for depressive symptoms in 
people with ALS, with a sensitivity of 100% and specificity 
of 82%, meaning all people with a major depressive disorder 
were identified [36]. However, this tool focuses only on the 
evaluation of depression and does not account for the range 
of neuropsychiatric symptoms which may affect people with 
ALS.
The other tools used in the trials included in this review 
are Beck’s Depression Inventory (BDI) [37], Hamilton 
Depression Inventory (HAM-D) [38], Columbia Suicide 
Severity Score (C-SSRS) [39], Hosptial Anxiety and Depres-
sion Scale (HADS) [40] and the Neuropsychiatric Inven-
tory Questionnaire (NPI-Q) [41]. The BDI and HAM-D are 
extensively validated [42, 43], well-established measures of 
depressive symptoms. However, their reliance on somatic 
features of depression mean scores may be confounded by 
physical decline and no ALS-specific impairment thresholds 
are available. The HADS is designed to reduce the focus on 
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somatic symptoms and ALS-specific impairment thresholds 
have been proposed [44].
The C-SSRS is considered a useful tool to structure dis-
cussions of suicidal ideation and intent [45]. However, the 
C-SSRS can be lengthy to administer, insufficient to cover 
the full spectrum of suicidal ideation [46] and responses to 
questions of end-of-life planning may be influenced by the 
presence of a terminal diagnosis. The NPI-Q is a validated 
informant-based questionnaire to evaluate the presence and 
severity of 12 neuropsychiatric domains [47].The ability of 
the tool to discriminate effectively between different disor-
ders has been questioned [48].
Of the eight trials that did assess cognitive and behaviour 
change as an outcome measure, six used tools where scor-
ing was unaffected by physical disability or communication 
impairment and were specifically designed, and validated, 
to identify domains impaired in people with ALS. One trial 
used the ALS Cognitive Behavioral Screen (ALS-CBS) [49] 
and five trials used the Edinburgh Cognitive and Behavioural 
ALS Screen (ECAS) [50].
The ALS-CBS is a brief assessment of executive func-
tions while the ECAS assesses a wider profile of cognitive 
and behavioural impairment in ALS including executive 
and language functions, fluency and social cognition. Both 
are designed to be completed by either written or spoken 
responses to be suitable for ALS patients with differing func-
tional ability. Additionally, ECAS scoring is also corrected 
for differences in motor speed during both speech and writ-
ing tasks, to accommodate for a range in disability severity.
Additionally, the Montreal Cognitive Assessment Scale 
(MoCA) [51], Addenbrooke’s Cognitive Examination (ACE-
III) [52] and Mini Mental State Examination (MMSE) were 
used to evaluate cognition in the trials reviewed. Although 
widely validated for use in neurological conditions, particu-
larly dementia, these tools were not specifically designed to 
assess the cognitive profile of people with ALS. As a result, 
Table 2  Quality of life assessment tools and areas assessed
Assessment name Total 
number of 
items
Number 
of trials 
utilised
Domains addressed Mood items
Amyotrophic lateral sclerosis 
assessment questionnaire-40 Item 
(ALSAQ-40)
40 14 Hopelessness, depression and emo-
tional reactivity
Ten items with 5-point Likert scale for 
frequency of mood symptoms
Amyotrophic lateral sclerosis 
assessment questionnaire-5 Item 
(ALSAQ-5)
5 6 Hopelessness One item with 5-point Likert scale on 
frequency of hopelessness
ALS specific quality of life 
(ALSQOL-R)
50 6 Depression and anxiety Ten-point Likert rating scales for 
level of agreement or frequency of 
experiences
EuroQol 5 domain assessment (EQ-
5D-5L)
5 4 Health perception and functional 
impact
Five-point Likert rating scale for 
severity of anxiety/depression 
combined
Edmonton symptom assessment 
system (ESAS)
10 1 Pain, depression, anxious and gen-
eral wellbeing
10-point Likert rating scale for depres-
sion and anxiety
McGill quality of life-revised 14 7 Depression, anxiety, mood and 
hopelessness
10-point Likert scale for severity of 
mood symptoms in previous 48 h
Schedule for the evaluation of indi-
vidual quality of life questionnaire 
(SEIQoL)
3 1 Self-reported areas of concern and 
effect on function
Identify five most important areas in 
their life and rate importance
Short form patient questionnaire – 12 
item (SF-12)
12 3 Emotional problems Two items identifying the extent to 
which emotional problems affected 
activities
Short form patient questionnaire – 36 
item (SF-36)
36 6 Low mood, lack of energy, anxiety Four items identifying the extent to 
which emotional problems affected 
activities
Sickness impact profile – ALS Items 
(SIP/ALS-19)
19 1 ALS-adapted SIP Focus on activi-
ties of daily living, self-care and 
activities
No items specifically focused on 
mood, 1 item on social interaction
Visual analogue scale (VAS—3 
health status questions)
3 1 General, physical and mental health 
self-rating
0–100 scale for overall mental health
Visual analogue scale and patient’s 
global impression of change
2 1 Pain and self-perception of health 7-point and 10-point Likert rating 
scales for change in emotion and 
overall quality of life
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no ALS-adapted thresholds for impairment were available 
and scoring on the tools was potentially impacted by motor 
decline experienced in ALS.
Verbal fluency is a commonly found deficit in ALS and is 
included as a sub-test on other cognitive assessments identi-
fied in this review and as a standalone test of cognition in 
one trial. However, it was not clear from the trial record if 
motor speed was controlled for in the assessment which can 
affect interpretation of the scores [12].
The Frontal Behavior Inventory (FBI) [53] and the behav-
ioural interview of the ECAS and ALS-CBS were utilised to 
screen for behavioural symptoms which may be indicative 
of fronto-temporal dementia.
An additional assessment tool utilised by one trial, to 
exclude individuals with an intellectual disability, is the 
Weschler Adult Intelligence Scale (WAIS) [54]. As the 
WAIS was intend to screen for lower intelligence quotients 
rather than specific cognitive impairments we have not 
included this tool in Table 3 which focuses specifically on 
tools used to assess neuropsychiatric symptoms and cogni-
tive impairment.
Table 3  Characteristics of tools used to evaluate cognition and neuropsychiatric symptoms
 + Test designed or adapted for ALS and ALS-specific impairment thresholds are available
−Test not designed/adapted for ALS and no ALS-specific impairment thresholds currently available
NB Time to administer is indicated as a guide only. This will vary depending upon the respondent’s functional ability, presence of a communica-
tion impairment and use of assistive devices and the researcher’s experience in administering the instrument
Area assessed in 
trials
Domains Designed for, or 
adapted for ALS with 
abnormality cut-offs
Administra-
tion time 
(min)
Total score References
Beck’s depression 
inventory
Depression Depression  − 5–10 63 [37]
Columbia suicide 
severity score
Suicidality Suicidality  − 5–30 Binary outcome of 10 
categories
[39]
Hamilton depression 
scale
Depression Depression  − 20–30 52 [38]
Hospital anxiety and 
depression scale
Anxiety and depres-
sion
Anxiety and depres-
sion
 + 5–10 21 per disorder [40, 44]
Neuropsychiatric 
inventory question-
naire
Depression Neuropsychiatric 
conditions
− 5 100 for 10-item & 
144 for 12-item
[41, 47]
Amyotrophic lateral 
sclerosis depression 
inventory
Depression Depression  + 5 48 [36, 66]
Amyotrophic lateral 
sclerosis cognitive 
behavioural screen
Cognition and behav-
iour
Executive functioning 
and behaviour
 + 5–10 20 for cognitive 
section
[49, 61]
Addenbrooke’s cogni-
tive examination
Cognition Attention, memory, 
verbal fluency, 
language and  
visuospatial
 − 15 + 100 [67]
Montreal cognitive 
assessment
Cognition General cognition  − 10–15 30 [51, 68]
Edinburgh cognitive 
and behavioural 
assessment screen
Cognition and behav-
iour
Executive function-
ing, language, 
fluency, memory, 
visuospatial, social 
cognition, verbal 
fluency index and 
behaviour
 + 15–25 136 for cognitive 
section
[50]
Frontal behavioural 
inventory
Behaviour Behaviours character-
istic of FTD
 − 15–30 Severity rating 0–3 
on 24 items
[53, 69]
Verbal fluency Cognition Language  +  < 5 N/A [12, 53]
Mini mental state 
examination
Cognition General cognition  −  < 5 30 [70]
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Discussion
This review of 216 clinical trials from the last 25 years of 
ALS research highlights that the assessment of neuropsychi-
atric and cognitive symptoms has been frequently neglected. 
Only one trial assessed the impact of the candidate drug on 
both neuropsychiatric symptoms and cognitive impairment. 
This is despite overwhelming evidence that these extra-
motor features are prevalent across, and impactful upon, 
people with ALS [5, 9, 20].
Whilst the impact on physical functioning and survival 
justifiably remain the primary objectives for clinical tri-
als of ALS, the importance of additional assessments for 
neuropsychiatric and cognitive functioning needs to be 
addressed. This will enable future trial design to align with 
the 2019 revision of Airlie House consensus guidelines, rec-
ommendations for the design and implementation of clinical 
trials in ALS [30].
As the only globally licensed treatment for ALS, riluzole 
use is sometimes an exclusion criteria, or a minimisation 
criteria at point of randomisation, in many ALS trials. The 
effect of riluzole on cognition in people with ALS is not yet 
established, with study results reporting variable impact [56, 
57]. Frequent inclusion in trials in other neurological con-
ditions, and conflicting findings, provides further justifica-
tion for the inclusion of cognitive measures to evaluate how 
established medications such as riluzole, and exploratory 
study drugs, impact upon people with ALS.
Assessment of neuropsychiatric symptoms 
in clinical trials
Despite research indicating the presence of neuropsychiatric 
symptoms and comorbidities as pervasive [3, 55] and per-
nicious [56] in people with ALS, the impact of candidate 
drugs on neuropsychiatric functioning is underevaluated. Of 
the 216 trials included in this review, only eight reported 
using a formal neuropsychiatric assessment tool. Accuracy 
of evaluation is additionally hindered by the limited avail-
ability of tools specifically designed and validated for neu-
ropsychiatric evaluation of the ALS population. To evaluate 
the impact of candidate drugs on neuropsychiatric domains 
potentially affected in ALS, without significant confounding 
of physical disability, a greater understanding of the validity 
of these measures in ALS trials is needed.
Assessment of cognition in clinical trials
The past 15 years of research has highlighted the ubiquity of 
cognitive and behavioural impairment in people with ALS, 
[50, 57]. Whilst the assessment of these changes has become 
widely accepted in clinical care for people with ALS [58], 
clinical trials are lagging behind, with only 21% of the 216 
trials reviewed in this study assessing cognition.
The inclusion of cognitive assessment in clinical trial 
design as an additional outcome measure is progressing 
slightly. In the previous decade of research, 2010–2020 
inclusive, 7% (n = 6) of 86 trials registered, commenced 
or published within this time frame assessed cognition as 
an outcome measure. In comparison, of 101 trials from the 
decade prior, 2000–2010, 2% (n = 2) assessed cognition as 
an outcome measure.
Cognitive assessment in trial design is also increasing in 
accuracy, in part due to the availability of ALS-specific tools 
validated specifically to assess the domains impaired in this 
cohort [49, 59], particularly the ALS Cognitive Behavioral 
Screen (ALS-CBS) and Edinburgh Cognitive and Behav-
ioural ALS Screen (ECAS) in the trials reviewed here. Cog-
nitive assessments used previously may not be suitable for 
individuals with physical disabilities, due to an over-reliance 
on motor tasks, and limited focus on cognitive domains 
impaired in people with ALS.
Our review focused on the inclusion of cognitive func-
tioning assessment in trial design; however, assessing evo-
lution in in cognitive functioning during disease trajectory 
may also be of interest in future trial design. Longitudinal 
cognitive assessments were evaluated as an outcome meas-
ure in the ALS Multicenter Cohort Study of Oxidative 
Stress (ALS COSMOS [60]). Baseline data in this study 
of 247 participants evaluated with the ALS-CBS indicated 
that cognitive and behavioural impairments were common, 
6.5% scoring below cut-offs for frontotemporal dementia 
[49], 54.2% scoring consistent with mild cognitive impair-
ment and behavioural subscores outwith the normal range 
in 30.6% of responders [61]. Analysis of longitudinal data 
did not detect cognitive decline over a 12-month period but 
did detect an increase in behavioural changes, notably dis-
inhibition, while initial behavioural impairment predicted 
attrition [62]. Other studies have demonstrated increasing 
prevalence of cognitive and behavioural impairment in later 
disease stages [63, 64].
Non-interventional studies which have assessed change 
in cognition over time have shown mixed results [64, 65]. 
Attrition of individuals with cognitive and/or behavioural 
impairments from longituinal repeated assessments may also 
bias the sample towards individuals with slower disease pro-
gression and more stable cognitive functions.
Only one trial in this review, the Omigapil trial 
(NCT00072709), reported data on cognitive otucomes. No 
change in neurocognitive secondary outcome measure was 
reported, with the Addenbrooke’s Cognitve Examination 
(ACE) [34]. Understanding of cognitive change across the 
disease course is of prime importance for the interpretation 
of cognitive data in clinical trials.
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Impact on generalisability of trial findings
A diagnosis, historical or current, of symptoms of a neu-
ropsychiatric disorder was still explicitly identified as an 
exclusion criterion for the majority of trials included in this 
study.
Cognitive impairment was also often included as an 
exclusion criterion, with thresholds for impairment often 
subjective or not addressed. This could be due to research-
ers’ concerns over capacity to consent, potential issues with 
trial adherence, compliance with assessments and follow-
ing medication regimens.
Ultimately, results from studies with strict exclusion 
criteria, which reduce the sample representativeness of a 
heterogenous patient group, may not be generalisable to the 
whole ALS population. Furthermore, excluding individuals 
with neuropsychiatric conditions and cognitive impairment, 
unless when absolutely necessary, and neglecting to include 
these aspects as outcome measures, misses a vital opportu-
nity to explore how candidate drugs may affect people with 
ALS across this diverse condition.
Conclusion
This study clearly demonstrates that the impact of candidate 
drugs on neuropsychiatric symptoms and cognition has been 
under-evaluated in clinical trials and that when these symp-
toms have been evaluated, the tools used may not be suitable 
for people with ALS.
Accurate identification of neuropsychiatric comorbid-
ity and cognitive impairment is an essential requirement to 
improve our understanding of how candidate drugs impact 
the extra-motor features of ALS.
We recommend the evaluation of neuropsychiatric and 
cognitive symptoms as additional outcome measures in 
clinical trials of investigative medicinal products. Addition-
ally, when evaluating these areas we recommend using tools 
which are designed to assess domains affected in ALS, with 
disease-specific impairment thresholds and those adapted to 
account for motor decline and communication difficulties.
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